Prognostic Significance of Fatty Liver Index for the Development of Hypertension and Cardiovascular Events in

Youngnam Bok1, Jae-Hyung Roh2, Soo Yeon An1

  • 1Divison of Cardiology, Department of Internal Medicine, Chungnam National University Hospital, Chungnam National University College of Medicine, Daejeon, Korea.

Insights

Suboptimal blood pressure (BP) increases hypertension risk. A higher fatty liver index (FLI) independently predicts new hypertension and adverse cardiovascular events in adults with suboptimal BP.

Area of Science:

  • Cardiology
  • Hepatology
  • Public Health

Background:

  • Suboptimal blood pressure (BP) precedes hypertension and is linked to morbidity and mortality.
  • Non-alcoholic fatty liver disease (NAFLD) is a growing metabolic disorder associated with cardiovascular diseases (CVDs).

Purpose of the Study:

  • To investigate the association between the fatty liver index (FLI) and incident hypertension.
  • To examine the link between FLI and major adverse cardiac and cerebrovascular events (MACCEs) in adults with suboptimal BP.

Main Methods:

  • A cohort of 179,028 Koreans with suboptimal BP and no traditional risk factors was analyzed.
  • Participants were categorized into 'normal BP' and 'high-normal BP' groups.
  • Cox proportional hazards regression assessed the association between FLI quartiles and outcomes.

Main Results:

  • New-onset hypertension developed in 19.36% of participants over 8.3 years, with higher incidence in the 'high-normal BP' group.
  • Higher FLI quartiles were significantly associated with increased hypertension risk in both BP groups.
  • MACCEs occurred in 1.87% of participants, with higher frequency in the 'high-normal BP' group. Elevated FLI was independently associated with increased MACCE risk.

Conclusions:

  • A higher FLI is an independent predictor of new-onset hypertension and MACCEs in Korean adults with suboptimal BP.
  • The FLI may serve as a valuable tool for identifying individuals at high risk for hypertension and adverse cardiovascular outcomes.
Abstract

Related Concept Videos

Ultrasound II: Endoscopic Ultrasound and FibroScan01:25

Ultrasound II: Endoscopic Ultrasound and FibroScan

Endoscopic Ultrasound (EUS) and FibroScan are valuable diagnostic tools in gastroenterology and hepatology, each with specific applications and techniques.
Endoscopic Ultrasound (EUS):
209
Blood Studies for Cardiovascular System III: Serum Lipid Profile01:25

Blood Studies for Cardiovascular System III: Serum Lipid Profile

Understanding serum lipids is crucial for maintaining cardiovascular health and preventing heart disease and stroke.
Serum lipids are fats and fatty substances in the blood and are crucial for various bodily functions, including energy storage, cellular structure, and hormone production. Serum lipids consist of cholesterol, triglycerides, and phospholipids.
Cholesterol is a soft, fat-like substance found in all body cells. It is crucial for producing hormones, vitamin D, and substances that aid...
298
Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers01:19

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
222
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
41
Hypertension III: Clinical Manifestations and Diagnostic Studies01:30

Hypertension III: Clinical Manifestations and Diagnostic Studies

Hypertension is asymptomatic and also referred to as the "silent killer" until it progresses to a severe stage or causes target organ disease. Patients may experience symptoms stemming from the strain on blood vessels and tissues in various organs or the heart's increased workload.Physical exams might show no abnormalities other than high blood pressure. Signs of vascular damage, when present, correspond to the organs supplied by the affected vessels, leading to target organ damage. For...
54
Factors affecting Blood pressure01:28

Factors affecting Blood pressure

Several physiological and lifestyle factors influence blood pressure (BP). Understanding these factors is crucial as they are significant in patient education and blood pressure management.
Physiological Factors:
5.0K